Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) and Dominari (NASDAQ:DOMH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.
Risk & Volatility
Enlivex Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
Institutional and Insider Ownership
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enlivex Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Dominari | 1 | 0 | 0 | 0 | 1.00 |
Enlivex Therapeutics currently has a consensus target price of $247.50, indicating a potential upside of 4,138.01%. Given Enlivex Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Dominari.
Valuation and Earnings
This table compares Enlivex Therapeutics and Dominari”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enlivex Therapeutics | N/A | N/A | $1.24 billion | ($8.25) | -0.71 |
| Dominari | $123.10 million | 0.53 | -$22.43 million | ($4.03) | -0.72 |
Enlivex Therapeutics has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Enlivex Therapeutics and Dominari’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enlivex Therapeutics | N/A | 248.08% | 206.39% |
| Dominari | -31.37% | -206.20% | -155.26% |
Summary
Enlivex Therapeutics beats Dominari on 9 of the 13 factors compared between the two stocks.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
